Quick Answer
OnKure Therapeutics, Inc. reported Net Income of -$59.52 million for fiscal year 2025.
OnKure Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$59.52M -13.0% |
-$52.67M -49.2% |
-$35.31M +32.0% |
-$51.95M -30.6% |
-$39.77M -104.3% |
-$19.46M |
| Diluted EPS | -$4.40 +71.2% |
-$15.28 +87.7% |
-$124.41 -5768.4% |
-$2.12 +3.2% |
-$2.19 +77.2% |
-$9.60 |
| Total Assets | $62.12M -45.9% |
$114.91M +221.6% |
$35.73M -67.0% |
$108.18M -29.8% |
$154.02M +178.9% |
$55.22M |
| Cash and Equivalents | $59.05M -46.7% |
$110.76M +270.7% |
$29.88M +49.9% |
$19.93M -84.0% |
$124.66M +132.5% |
$53.61M |
| Stockholders Equity | $56.18M -45.9% |
$103.83M +202.0% |
-$101.84M -87.1% |
-$54.42M -137.0% |
$147.21M +449.5% |
-$42.12M -82.1% |
| R&D Expense | $48.26M +10.2% |
$43.80M +36.4% |
$32.12M -14.8% |
$37.70M +33.9% |
$28.17M +76.7% |
$15.94M |
| Operating Income | -$62.95M -15.7% |
-$54.39M -47.3% |
-$36.93M +31.4% |
-$53.85M -35.2% |
-$39.82M -103.7% |
-$19.55M |
| Shares Outstanding | — | — | 33.42M +35.3% |
24.70M +1.0% |
24.46M +1091.2% |
2.05M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$14.70M | -27.2% | +4.5% |
| Diluted EPS | September 30, 2025 | -$1.09 | +97.0% | +4.4% |
| Total Assets | September 30, 2025 | $72.83M | -6.2% | -15.4% |
| Cash and Equivalents | September 30, 2025 | $70.33M | +15.9% | -15.6% |
| Stockholders Equity | September 30, 2025 | $66.43M | +149.2% | -15.0% |
| R&D Expense | September 30, 2025 | $11.91M | +17.8% | -5.5% |
| Operating Income | September 30, 2025 | -$15.50M | -34.7% | +5.0% |
| Shares Outstanding | September 30, 2024 | 3.34M | -90.1% | -90.0% |
- OnKure Therapeutics, Inc. reported Net Income of -$59.52 million for fiscal year 2025.
- OnKure Therapeutics, Inc. showed a decrease of -13.0% in Net Income compared to the prior fiscal year.
- OnKure Therapeutics, Inc. reported Diluted EPS of $4.40 per share (loss) for fiscal year 2025.
- OnKure Therapeutics, Inc. showed an increase of +71.2% in Diluted EPS compared to the prior fiscal year.
- OnKure Therapeutics, Inc. reported Total Assets of $62.12 million for fiscal year 2025.
- OnKure Therapeutics, Inc. showed a decrease of -45.9% in Total Assets compared to the prior fiscal year.
- OnKure Therapeutics, Inc. reported Cash and Equivalents of $59.05 million for fiscal year 2025.
- OnKure Therapeutics, Inc. showed a decrease of -46.7% in Cash and Equivalents compared to the prior fiscal year.
- OnKure Therapeutics, Inc. reported Stockholders Equity of $56.18 million for fiscal year 2025.
- OnKure Therapeutics, Inc. showed a decrease of -45.9% in Stockholders Equity compared to the prior fiscal year.
- OnKure Therapeutics, Inc. reported R&D Expense of $48.26 million for fiscal year 2025.
- OnKure Therapeutics, Inc. showed an increase of +10.2% in R&D Expense compared to the prior fiscal year.
- OnKure Therapeutics, Inc. reported Operating Income of -$62.95 million for fiscal year 2025.
- OnKure Therapeutics, Inc. showed a decrease of -15.7% in Operating Income compared to the prior fiscal year.
- OnKure Therapeutics, Inc. reported Shares Outstanding of 33.42 million shares for fiscal year 2023.
- OnKure Therapeutics, Inc. showed an increase of +35.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: